SpyBiotech

SpyBiotech is a clinical-stage biotechnology company that spun out of the University of Oxford in 2017. The company was co-founded by Sumi Biswas, Simon Draper, Jing Jin, and Mark Howarth, who developed the core technology in the university's Department of Biochemistry and Jenner Institute. The founding research, which began in 2007, explored the 'surprising chemistry' of the bacterium *Streptococcus pyogenes*. This led to the development of the company's proprietary SpyTag/SpyCatcher protein "superglue" technology, which enables the rapid and stable attachment of antigens to vaccine delivery platforms.

The company's business model revolves around developing its own vaccine candidates and licensing its platform technology to partners. A key partnership includes an exclusive global licensing agreement with the Serum Institute of India to develop a COVID-19 vaccine, which has undergone clinical trials. SpyBiotech's primary clients are in the global healthcare and biopharmaceutical sectors. The company's main product is its vaccine platform, which includes the SPYVLP (Virus-Like Particle) and SPYVECTOR technologies. This platform addresses a common problem in vaccine development where traditional methods of attaching antigens to delivery particles can be imprecise and damage the components, rendering the vaccine ineffective. SpyBiotech's technology creates a spontaneous and irreversible covalent bond, allowing for controlled and stable vaccine assembly that can induce a robust immune response.

Since its inception with seed funding from Oxford Science Enterprises and GV (formerly Google Ventures), SpyBiotech has secured significant financing, including a $32.5 million Series A round in 2021 and a $4.09 million grant from the Bill & Melinda Gates Foundation in 2023. These funds are advancing the clinical development of its vaccine pipeline. The company's lead internal candidate is a vaccine for human cytomegalovirus (HCMV), which entered Phase I clinical trials in late 2023. SpyBiotech is also developing vaccines for other targets, including Epstein-Barr Virus (EBV).

Keywords: vaccine platform, protein superglue, SpyTag/SpyCatcher, clinical-stage biotechnology, infectious diseases, cytomegalovirus (CMV), virus-like particle (VLP), Oxford University spinout, immunology, vaccine development, covalent bonding, antigen presentation, biopharmaceutical, SpyVector, Epstein-Barr Virus (EBV), adenoviral vectors, prophylactic vaccines, therapeutic vaccines, bioconjugation